GBP2 and hematologic disorder: In addition, we examined the changes in GBP2, BAK, and MCL-1 protein levels following exposure to the main chemotherapeutic agents used for the treatment of hematological malignancies, including doxorubicin, cytarabine, vincristine, etoposide, and interferon-γ.